Literature DB >> 8738764

Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.

B B Rasmussen1, K Brøsen.   

Abstract

Caffeine metabolism via the 3-demethylation pathway is sequentially catalyzed by cytochrome P4501A2 (CYP1A2), xanthine oxidase, and N-acetyltransferase. The activities of the three enzymes can be estimated from urinary metabolic ratios of four caffeine metabolites, 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 1-methyluric acid (1MU), 1-methylxanthine (1MX), and 1,7-dimethyluric acid (17DMU), after the ingestion of caffeine. A method for quantitation of the four metabolites in human urine has been developed. The method is based on a one-step extraction with ethyl acetate/2-propanol followed by high-performance liquid chromatography with UV detection. The detection limit was 1 microM for AFMU, 1MU, and 1MX and 2 microM for 17DMU. The intraday and interday coefficients of variation were < 3% and < 7%, respectively, and the accuracy was within +/- 3%. The method was employed in a population study of 277 healthy volunteers, each of whom ingested 200 mg caffeine and provided a urine sample approximately 6 h later. The metabolite concentration ranges in the urines were 2.1-327 microM, 4.0-744 microM, 4.9-598 microM, and 6.4-260 microM for AFMU, 1MU, 1MX, and 17DMU, respectively. The CYP1A2 ratio (AFMU + 1MU + 1MX/17DMU) was significantly lower in women than in men, excluding smokers and oral contraceptive users. The CYP1A2 ratio was higher in smokers than in nonsmokers, confirming the induction of CYP1A2 by smoking. In women using oral contraceptives, the CYP1A2 ratio was, as expected, significantly lower than in women not using oral contraceptives. For the N-acetyltransferase ratio (AFMU/1MX) and the xanthine oxidase ratio (1MU/1MX), no differences were seen in terms of sex, smoking habits, or the use of oral contraceptives. All results are in agreement with previous reports on CYP1A2, N-acetyltransferase, and xanthine oxidase activities in humans. Thus, the method is both analytically and biologically reliable for the assessment of CYP1A2, N-acetyltransferase, and xanthine oxidase in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738764     DOI: 10.1097/00007691-199606000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  18 in total

1.  Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.

Authors:  Mia Birkhøj Kjærstad; Flemming Nielsen; Lene Nøhr-Jensen; Stine Zwisler; Kim Brøsen; Helle Raun Andersen
Journal:  Eur J Clin Pharmacol       Date:  2010-10-06       Impact factor: 2.953

2.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 4.  Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Authors:  Carsten Skarke; Anja Kirchhof; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

5.  A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Authors:  J B Dumond; M Vourvahis; N L Rezk; K B Patterson; H-C Tien; N White; S H Jennings; S O Choi; J Li; M J Wagner; N M La-Beck; M Drulak; J P Sabo; M A Castles; T R Macgregor; A D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2010-02-10       Impact factor: 6.875

Review 6.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

7.  Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples.

Authors:  A Nordmark; S Lundgren; S Cnattingius; A Rane
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

8.  In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.

Authors:  Natasa Djordjevic; Juan Antonio Carrillo; Guillermo Gervasini; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-02-13       Impact factor: 2.953

9.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

10.  A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers.

Authors:  Rasmus Steen Pedersen; Per Damkier; Mette Marie Hougaard Christensen; Kim Brosen
Journal:  Eur J Clin Pharmacol       Date:  2013-08-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.